|
Drug Metabolism, Poor, CYP2D6-Related
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
|
|
|
|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Elastosis perforans serpiginosa
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
1.The aim of the present study was to examine the relationship between CYP2D6 polymorphisms and the risk of antipsychotic (AP)-induced extrapyramidal symptoms (EPS) in patients receiving AP treatment.
|
18346175 |
2008 |
|
EAR, PATELLA, SHORT STATURE SYNDROME
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
1.The aim of the present study was to examine the relationship between CYP2D6 polymorphisms and the risk of antipsychotic (AP)-induced extrapyramidal symptoms (EPS) in patients receiving AP treatment.
|
18346175 |
2008 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
|
Depressed mood
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
|
CNS disorder
|
0.030 |
AlteredExpression
|
group |
BEFREE |
25-HC is elevated in patients with inflammatory CNS disease probably as a consequence of up-regulation of the type 1 interferon-stimulated gene cholesterol 25-hydroxylase in macrophages.
|
27878760 |
2017 |
|
Reoviridae Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
25-Hydroxycholesterol Production by the Cholesterol-25-Hydroxylase Interferon-Stimulated Gene Restricts Mammalian Reovirus Infection.
|
29950420 |
2018 |
|
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
47 patients with Major Depressive Disorder, treated with V 75 - 300 mg/day, underwent CYP2D6 genotyping using the INFINITI-CYP2D6 assay.
|
24660534 |
2014 |
|
Unipolar Depression
|
0.380 |
Biomarker
|
disease |
PSYGENET |
47 patients with Major Depressive Disorder, treated with V 75 - 300 mg/day, underwent CYP2D6 genotyping using the INFINITI-CYP2D6 assay.
|
24660534 |
2014 |
|
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risks for the CYP2D6 PM genotype amongst light smokers (tobacco consumption </=20 g/day) or heavy smokers (>20 g/day) were not significantly different.
|
10974631 |
2000 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risks for the CYP2D6 PM genotype amongst light smokers (tobacco consumption </=20 g/day) or heavy smokers (>20 g/day) were not significantly different.
|
10974631 |
2000 |
|
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risks for the CYP2D6 PM genotype amongst light smokers (tobacco consumption </=20 g/day) or heavy smokers (>20 g/day) were not significantly different.
|
10974631 |
2000 |
|
Dyskinetic syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
|
12432967 |
2002 |
|
Caffeine related disorders
|
0.070 |
Biomarker
|
group |
BEFREE |
Caffeine and debrisoquine were used as measures of CYP1A2 and CYP2D6, respectively.
|
12640212 |
2003 |
|
Hepatitis C
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Hepatitis C positive individuals were associated with a lower liver CYP2D6 enzyme activity.
|
21677335 |
2011 |
|
Ecstasy related disorders
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT.
|
22303032 |
2012 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer physicians were most likely to recommend BRCA1/2 mutation testing (73%) and least likely to recommend CYP2D6 genotyping (12%), while patients were more likely to choose Oncotype DX testing (28%) over CYP2D6 (21%) and BRCA1/2 testing (15%).
|
22560561 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer physicians were most likely to recommend BRCA1/2 mutation testing (73%) and least likely to recommend CYP2D6 genotyping (12%), while patients were more likely to choose Oncotype DX testing (28%) over CYP2D6 (21%) and BRCA1/2 testing (15%).
|
22560561 |
2013 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer patients (n = 141) on adjuvant tamoxifen and not on any concomitant CYP2D6 inhibitors were recruited for the study.
|
22623212 |
2012 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer patients (n = 141) on adjuvant tamoxifen and not on any concomitant CYP2D6 inhibitors were recruited for the study.
|
22623212 |
2012 |